Vonoprazan Fumarate Powder CAS 1260141-27-2

Vonoprazan Fumarate Powder is the fumarate salt​ of Vonoprazan, an innovative, potent, and long-acting active pharmaceutical ingredient (API) belonging to a novel drug class called Potassium-Competitive Acid Blockers (P-CABs). It is primarily used for the treatment of acid-related gastrointestinal disorders.

1. Innovative Mechanism of Action:
Unlike traditional Proton Pump Inhibitors (PPIs) like omeprazole, which require acid activation and have a delayed effect, Vonoprazan Fumarate Powder works through a distinct and advantageous mechanism:

It directly, reversibly, and competitively​ inhibits the gastric H⁺/K⁺-ATPase (the proton pump) by competing with potassium ions at the pump's active site.

It does not require activation in an acidic environment, allowing it to act immediately upon administration.

This results in a faster onset of action​ (achieving near-maximal acid suppression with the first dose), stronger acid inhibition, and more sustained 24-hour pH control, including superior control of nocturnal acid breakthrough.

2. Advantages Over Traditional PPIs:

• Predictable Efficacy:​ Its pharmacokinetics and acid-suppressing effect show minimal inter-patient variability and are largely unaffected by genetic differences in the CYP2C19 enzyme, ensuring consistent results.
• Convenient Dosing:​ Can be administered without strict regard to meals, improving patient compliance.
• Faster Symptom Relief:​ Due to its immediate action on active pumps.

3.Pharmaceutical Form:

The active moiety, Vonoprazan, is formulated as its fumarate salt​ to enhance the compound's stability, solubility, and overall pharmaceutical properties for oral dosage forms (typically film-coated tablets).

4. Market Status & Importance:
Approved in key markets including Japan, China, the United States, and several others, Vonoprazan Fumarate Powder represents a significant therapeutic advancement in gastroenterology. It is increasingly becoming a first-line or preferred option for acid suppression due to its superior clinical profile.

Vonoprazan Fumarate Powder(CAS NO. 1260141-27-2) is more than just an alternative to PPIs; it represents the new standard in acid suppression therapy. Its robust clinical profile, expanding range of applications, and potential for innovative combinations make it a high-value, strategic API for forward-thinking pharmaceutical companies.

TNJONE Products are designed for research and industrial use only. Not intended for clinical or medical purposes.

Hot Tags: vonoprazan fumarate powder cas 1260141-27-2, China vonoprazan fumarate powder cas 1260141-27-2 manufacturers, suppliers, factory, Empagliflozin Powder CAS 864070 44 0, Minoxidil Powder, L carnitine Powder CAS 541 15 1, 6990 06 03 00 00 00, Terbinafine Hydrochloride Powder, Diclofenac sodium Powder